ClinicalTrials.gg
Not yet recruitingNCT07739459ZEN-CLLUpdated Sep 14, 2026

Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by The Lymphoma Academic Research Organisation. Not yet recruiting at 17 sites in France. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by The Lymphoma Academic Research Organisation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
80 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 17 under way, 3 of them phase 3. zanubrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
9th of 22
95 · median 71
Started
2026
with 3 others
Phase 2
15 of 22
9 open now
Primary completion
2029-04
later than 13 of 16 live
Registered
21st of 22
by date

Among the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by planned enrollment, is one of 4 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 13 of the 16 other live ones, and was the 21st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 80 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This phase II, open-label, multicenter study evaluates zanubrutinib in patients aged 80 years and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who require treatment.

CLL and SLL are slow-growing blood cancers that mainly affect older adults. Although zanubrutinib is an effective treatment, taking it continuously at the full dose may increase the risk of side effects over time, particularly in elderly patients. The study aims to assess whether a planned reduction in the dose of zanubrutinib after an initial period of treatment can maintain disease control while improving long-term tolerability.

Read the detailed description

The ZEN-CLL study is evaluating a treatment strategy based on zanubrutinib in previously untreated elderly patients with CLL or small lymphocytic lymphoma (SLL). Approximately 95 participants will be enrolled in 17 LYSA centers in France.

All participants will receive zanubrutinib 160 mg twice daily for the first 18 months of treatment. After Month 18, the dose will be reduced according to the dose received at that time and the participant's tolerability. Treatment will continue until permanent treatment discontinuation or the end of study participation.

The study aims to determine whether this dose reduction strategy can maintain disease control while improving long-term tolerability in this elderly population.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma
  • Zanubrutinib
  • BTK inhibitor
  • First-line treatment
  • Treatment-naïve patients
04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant who understands and voluntarily signs and dates an form prior to any studyspecific assessments/procedures being conducted, including consent for specific biology analysis
  • Must be able to adhere to the trial visit schedule and other protocol requirements
  • ≥ 80 years at the time of signing the informed consent form (ICF) with no upper age limit
  • Previously untreated and documented CLL or small lymphocytic lymphoma (SLL), with a Royal Marsden Hospital (RMH) or Matutes Score of 4 or 5. For SLL a detectable clone with a CLL phenotype in the peripheral blood is a prerequisite for trial participation.
  • Participant requiring treatment according to 2018 IWCLL guidelines
  • performance status 0 to 2
  • > 6 months
  • Adequate hematopoietic function within 7 days before the participant's enrollment

    • ≥ 0.75 G/L
    • And ≥ 50 G/L Note: Platelets transfusions may be administered during screening to meet this requirement
  • level > 9g/dL, regardless of transfusion
  • Adequate renal function defined by a ≥ 30 ml/min calculated according to or CKD-EPI or Cockcroft-Gault (using actual body weight).
  • Adequate liver function, as indicated by a total \<1.5 x , and ALT \<3 x ULN value, unless directly attributed to the participant's CLL/SLL or to Gilbert's Syndrome (the ULN is based on institutionalvalues)
  • Participant covered by any social security system
  • Participant who understands and speaks the country official language unless local regulation authorizes independent translator

Exclusion criteria

Exclusion Criteria:

  • Any prior CLL or SLL-specific therapies, even including rituximab used for cytopenias.
  • cardiovascular disease including the following:

    1. Myocardial infarction within 6 months prior to ICF signature
    2. Unstable angina within 3 months prior to ICF signature
    3. class III or IV heart failure
    4. Uncontrolled hypertension
    5. History of clinically significant arrhythmias (including sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes).
    6. History of Mobitz II second- or third-degree heart block without permanent pacemaker
    7. Known \<50% as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
  • liver cirrhosis
  • Clinical evidence for Central Nervous System involvement by CLL
  • Severe chronic obstructive lung disease with hypoxemia
  • Severe diabetes mellitus
  • Disease significantly affecting gastrointestinal function (malabsorption syndrome, stomach or small bowel resection)
  • Active or non-active autoimmune hemolytic anemia (AIHA) (isolated positive DAT is not an exclusion criterion, but reticulocytes/haptoglobin levels must be in lab normal ranges) or idiopathic thrombocytopenic purpura (ITP), requiring therapy with > 20 mg daily of prednisone dose or equivalent.
  • Any prior history of Richter transformation or DLBCL
  • Any evidence or suspicion of Richter transformation or DLBCL during screening
  • Active other than the one treated in this trial. Prior history of malignancies unless the participant has been free of the disease for ≥ 2 years.

However, participants with the following history /conditions that have been treated with a curative intent are allowed:

  1. Non-invasive basal cell or epidermoid carcinoma (non melanoma)
  2. In situ carcinoma of the cervix
  3. In situ carcinoma of the breast
  4. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, [TNM] clinical staging system
  5. Woman with endocrine therapy (I.e., hormonotherapy) after breast cancer treatment can be enrolled if hormonotherapy was started for ≥ 2 years

    • History of stroke or intracranial hemorrhage within 6 months prior to ICF signature.
    • Major surgery 28 days before the ICF signature
    • History or known bleeding disorders (e.g hemophilia or von Willebrand disease)
    • Active Virus (HCV) infection (RNA PCR-positive). Participants who received treatment for HCV infection that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable
    • Active Virus (HBV) infection (DNA PCR-positive). Participants with evidence of prior HBV infection but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy during the entire treatment with active monitoring of viral load in the blood
    • Patient with a positive test before enrollment are eligible provided that they are stable on antiretroviral therapy for at least 4 weeks, have a ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months.Known or suspected or anaphylaxis to trial intervention including active substance or to any of the .
    • Requires or receiving anticoagulation with warfarin or dual antiplatelets therapy equivalent vitamin K antagonists (other anticoagulants allowed: novel oral anticoagulant alone, aspirin alone, heparin alone).
    • Requires treatment with a strong/moderate cytochrome inhibitor/inducer.
    • Participation in another clinical study who would compromise the participation to the current study.
    • Vaccinated with live, attenuated vaccines within 6 months of ICF
    • Use of any standard or experimental anti-cancer drug therapy within 28 days before the start (Day 1) of study treatment
    • Corticosteroid use > 20 mg per day within 1 week before the first dose of trial intervention, except as indicated for other medical conditions, such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of trial intervention or contrast.
    • Any significant medical conditions, or laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical trial or affect interpretation of trial outcomes (according to the investigator's decision)
    • Any uncontrolled and/or active significant infection (eg, bacterial, viral, or fungal; including participants with positive cytomegalovirus PCR).
    • Participant deprived of their liberty by a judicial or administrative decision
    • Participant hospitalized without consent
    • Adult participant under legal protection
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    Zanubrutinib

    Participants will receive oral zanubrutinib followed by a predefined dose reduction strategy. Treatment will continue until disease progression, permanent treatment discontinuation, withdrawal of consent, loss to follow-up, or the end of study participation.

    Drug: Zanubrutinib

Interventions

  • Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor administered orally.

    Also known as: BRUKINSA

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    The primary endpoint is the Progression-Free Survival (PFS).

    Time frame: 30 months and 5 years

Secondary outcomes

  1. Permanent Treatment Discontinuation (PTD) Rate

    The key secondary endpoint is the rate of permanent treatment discontinuation (PTD).

    Time frame: 18 months

  2. Overall Survival (OS)

    The secondary efficacy endpoint 1 is the Overall Survival (OS).

    Time frame: At 30 months and at 5 years

  3. Time to Next Anti-Leukemia Treatment

    The secondary efficacy endpoint 2 is the Time to Next Anti-Leukemia Treatment (TTNLT).

    Time frame: At 30 months and at 5 years

  4. Overall Response Rate

    The secondary efficacy endpoints 3 and 4 are Overall Response Rate (ORR) at 18 months and at 30 months, respectively.

    Time frame: At 18 months and at 30 months

  5. Change From Baseline in Geriatric Assessment Scores

    Geriatric condition will be evaluated using minimal nurse-delivered scales recommended by the SIOG.

    Time frame: at baseline, at 18 months, at 30 months and at 42 months

  6. Health-Related Quality of Life

    Health-Related Quality of Life as assessed by Questionnaire

    Time frame: At baseline, every 3 months for the first 2 years, and every 6 months thereafter for 3 years.

  7. Frailty Assessment Score

    Frailty status will be assessed using a validated frailty scale.

    Time frame: At baseline, every 3 months for the first 2 years, and every 6 months thereafter for 3 years.

  8. Patient-Reported Treatment Side Effect Burden

    Treatment side effect burden will be assessed using a patient-reported questionnaire.

    Time frame: Baseline, every 3 months for the first 2 years, and every 6 months thereafter for 3 years.

  9. Incidence and Severity of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    Safety will be assessed by the incidence, severity, and seriousness of adverse events, including serious adverse events and adverse events of special interest.

    Time frame: From first dose of study treatment until the end of study participation (up to 5 years).

07

Study locations

17 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2029, 28 months later.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 28 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartEst.
Dec 2026
Primary completionEst.
Apr 2029
CompletionEst.
Dec 2032
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07739459
Lead sponsor
The Lymphoma Academic Research Organisation
Collaborators
Lymphoma Study Association, BeOne Medicines
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Dec 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Dec 2032 (estimated)
Last update
Sep 14, 2026

Study contacts

Project management
Contact
zen-cll@lysarc.org
+33 4 72 66 93 33
Loïc YSEBAERT, Professor
principal investigator · IUCT ONCOPOLE
Emmanuelle FERRANT, Doctor
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion